↓ Skip to main content

Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect

Overview of attention for article published in PLOS ONE, October 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
1 news outlet
twitter
96 X users
facebook
121 Facebook pages
googleplus
6 Google+ users
reddit
4 Redditors

Citations

dimensions_citation
123 Dimensions

Readers on

mendeley
205 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect
Published in
PLOS ONE, October 2013
DOI 10.1371/journal.pone.0076918
Pubmed ID
Authors

Marta Solinas, Paola Massi, Valentina Cinquina, Marta Valenti, Daniele Bolognini, Marzia Gariboldi, Elena Monti, Tiziana Rubino, Daniela Parolaro

Abstract

In the present study, we found that CBD inhibited U87-MG and T98G cell proliferation and invasiveness in vitro and caused a decrease in the expression of a set of proteins specifically involved in growth, invasion and angiogenesis. In addition, CBD treatment caused a dose-related down-regulation of ERK and Akt prosurvival signaling pathways in U87-MG and T98G cells and decreased hypoxia inducible factor HIF-1α expression in U87-MG cells. Taken together, these results provide new insights into the antitumor action of CBD, showing that this cannabinoid affects multiple tumoral features and molecular pathways. As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.

X Demographics

X Demographics

The data shown below were collected from the profiles of 96 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 205 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
United Kingdom 1 <1%
Singapore 1 <1%
Unknown 199 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 13%
Researcher 26 13%
Student > Ph. D. Student 24 12%
Student > Bachelor 20 10%
Other 13 6%
Other 32 16%
Unknown 63 31%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 29 14%
Medicine and Dentistry 27 13%
Agricultural and Biological Sciences 27 13%
Pharmacology, Toxicology and Pharmaceutical Science 15 7%
Chemistry 10 5%
Other 26 13%
Unknown 71 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 122. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2023.
All research outputs
#348,777
of 25,804,096 outputs
Outputs from PLOS ONE
#4,944
of 224,989 outputs
Outputs of similar age
#2,608
of 225,389 outputs
Outputs of similar age from PLOS ONE
#120
of 5,169 outputs
Altmetric has tracked 25,804,096 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 224,989 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,389 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 5,169 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.